MedPath
HSA Approval

Clindamycin-hameln Solution for Injection 150mg/ml

SIN14599P

Clindamycin-hameln Solution for Injection 150mg/ml

Clindamycin-hameln Solution for Injection 150mg/ml

September 3, 2014

ZYFAS PHARMA PTE LTD

ZYFAS PHARMA PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantZYFAS PHARMA PTE LTD
Licence HolderZYFAS PHARMA PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, SOLUTION

INTRAVENOUS, INTRAMUSCULAR

Medical Information

J01FF01

clindamycin

Manufacturer Information

ZYFAS PHARMA PTE. LTD.

Siegfried Hameln GmbH

Active Ingredients

Clindamycin Phosphate 178.23 mg/ml eqv Clindamycin

150 mg/ml

Clindamycin

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Clindamycin-hameln Solution for Injection 150mg/ml - HSA Approval | MedPath